<DOC>
	<DOCNO>NCT00250042</DOCNO>
	<brief_summary>1.0 OBJECTIVES 1.1 To test activity arsenic trioxide combination imatinib patient CML cytogenetic evidence residual disease . 1.2 To determine toxicity associate therapy .</brief_summary>
	<brief_title>A Phase II Study Gleevec Arsenic Trioxide Patients With CML Who Fail Gleevec</brief_title>
	<detailed_description>- Chronic myelogenous leukemia ( CML ) result clonal expansion immature myeloid cell ( 9,22 ) ( Ph ) translocation , encode constitutively active tyrosine kinase oncogene , bcr/abl . Patients chronic phase CML currently treat either hemopoetic stem cell transplantation ( HSCT ) , recently approve tyrosine kinase inhibitor , imatinib . Previous data , use interferon patient CML , show patient achieve major cytogenetic response ( define &gt; 35 % Ph+ ) shorten survival . These patient often consider HSCT . However , due constraint age , suitable donor , patient choice , minority patient undergo potentially curative procedure . - The aim study create uniform approach treatment CML New Mexico , aim achieve complete cytogenetic response primary goal . A graded approach take , start standard treatment ( imatinib 400 mg per day ) , patient identify poor responder imatinib , arsenic combination offer patient . It hop find complete cytogenetic response exceed ~20 % response gleevec 800mg per day .</detailed_description>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : All patient , 18 year age old , diagnosis CML . Patients must life expectancy least 12 week . Patients must ECOG performance status 02 . Patients must sign informed consent . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . Patients CML chronic phase gleevec first line therapy fulfill follow criterion : Failure achieve complete hematologic response ( CHR ) 3 month therapy ( hematologic resistance ) Failure achieve complete cytogenetic response ( CGCR ) &gt; 9 month therapy . Cytogenetic relapse , define increase Ph+ cell least 30 % . Hematologic relapse define appearance following , confirm second determination &gt; 1 month later : WBC count &gt; 20 , 000 , Platelet count &gt; 600,000 , Progressive splenomegaly &gt; 5 cm leave intercostal margin , &gt; 5 % myelocyte and/or metamyelocytes peripheral blood , Blasts promyelocytes peripheral blood Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>